Deals du Jour
Japanese firm Dainippon Sumitomo Pharma Co Ltd (4506.T) agrees a $2.7 billion to buy Sepracor Inc (SEPR.O). Dainippon will acquire a 1,000-strong sales force and drugs to treat insomnia and epilepsy from U.S.-based Sepracor.
Thermo Fisher Scientific (TMO.N) has agreed a 330 million euro purchase of German firm Brahms, a manufacturer of disease diagnosis tests. Thermo Fisher, which makes scientific instruments, said the deal would open up promising opportunities for commercialising new patents.
For more on this and the latest Reuters deals news, click here.
And here’s a round-up of deal-related stories from Thursday’s press:
* The UK market regulator, the FSA, is stress-testing plans by banking group Lloyds (LLOY.L) to raise 10 billion pounds ($16.17 billion) and reduce its dependence on a state-backed toxic debt insurance scheme, the Daily Telegraph reported.
* Major shareholders of insurer RSA (RSA.L) would back plans by the company’s chief executive to raise $1 billion via a rights issue, the Daily Telegraph reported, citing some of the insurer’s largest institutional investors.
* Pfizer (PFE.N), the world’s largest drug company, may pay up to 1 billion reais ($525 million) to buy Brazilian generic drugmaker Neo Quimica, stepping up smaller acquisitions in fast-growing emerging markets, newspaper O Estado de S. Paulo said.
* Second-round bids for a majority stake in the Travel Channel have come in substantially ahead of early expectations with unforeseen private equity interest adding to demand from media companies, the Financial Times reported.
* General Motors Co expects the governments of Spain, Britain and Poland will provide it with 1 billion euros ($1.43 billion) in aid for its European Opel unit, the Wall Street Journal reported.